Neurocrine (NBIX) Chief Corp. Affairs Officer David Boyer Receives PRSUs, Sells Shares

What Happened
David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences (NBIX), had performance restricted stock units (PRSUs) vest on September 11, 2026 (3,587 shares granted at $0). To cover tax withholding, 1,936 shares were surrendered to the company at $156.22/share (value reported $302,442). Separately, 826 shares were sold in the open market on September 14, 2026 under a broker-directed Rule 10b5-1 plan at a weighted average price of $157.45/share (reported proceeds $130,051). Combined value of the withheld shares and sale is about $432,493. These actions represent a vesting (award) event followed by routine tax withholding and a prearranged sale.

Key Details

• Grant/vesting: 3,587 PRSUs certified vested on 2026-09-11 (acquisition price $0) (F1).
• Tax withholding: 1,936 shares withheld by the issuer to satisfy tax liabilities at $156.22/share; no open-market sale for withholding (F3). Reported value $302,442.
• Open-market sale: 826 shares sold on 2026-09-14 under a Rule 10b5-1 plan (adopted 2026-02-23). Weighted avg price $157.45; prices ranged $157.31–$157.5950 (F4, F5). Reported proceeds $130,051.
• Net shares retained from this vesting: 3,587 − 1,936 − 826 = 825 shares.
• The filing was submitted on 2026-09-15 covering transactions through 2026-09-14 (appears to be timely).
• Additional note: filing includes 98 shares purchased 2026-08-31 under the company ESPP (F2).

Context

• PRSUs vest when performance goals are met; the filing shows one performance metric was certified on Sept. 11, triggering the award.
• Surrendering shares to cover taxes is a routine cashless withholding and is coded as a disposition (F).
• The open-market sale was executed under a pre-set 10b5-1 plan (broker instructed); such sales are typically prearranged and should not be interpreted as ad-hoc trading based on nonpublic information.
• Retail investors: this filing primarily documents a vesting event with routine tax and prearranged sale actions rather than a discretionary, opportunistic insider sale.